DexCom Inc. (NASDAQ:DXCM) Receives Average Recommendation of “Buy” from Brokerages
Shares of DexCom Inc. (NASDAQ:DXCM) have been given a consensus recommendation of “Buy” by the nineteen brokerages that are presently covering the stock. Five research analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $96.82.
A number of research analysts recently issued reports on the stock. Jefferies Group restated a “buy” rating and set a $98.00 price objective on shares of DexCom in a report on Wednesday, August 3rd. Benchmark Co. decreased their price objective on shares of DexCom from $106.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday, August 3rd. Deutsche Bank AG boosted their price objective on shares of DexCom from $90.00 to $98.00 and gave the company a “buy” rating in a report on Friday, July 15th. Canaccord Genuity restated a “buy” rating and set a $95.00 price objective on shares of DexCom in a report on Wednesday, July 13th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of DexCom in a report on Monday, June 20th.
In related news, insider Jorge A. Valdes sold 32,000 shares of the company’s stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $79.36, for a total value of $2,539,520.00. Following the transaction, the insider now directly owns 123,667 shares in the company, valued at $9,814,213.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jeffrey Moy sold 12,843 shares of the company’s stock in a transaction dated Tuesday, July 19th. The shares were sold at an average price of $83.78, for a total transaction of $1,075,986.54. The disclosure for this sale can be found here. 2.80% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Bellwether Investment Group LLC acquired a new position in DexCom during the second quarter valued at approximately $119,000. Bank of Montreal Can acquired a new position in DexCom during the second quarter valued at approximately $134,000. CIBC Asset Management Inc acquired a new position in DexCom during the second quarter valued at approximately $211,000. ProShare Advisors LLC acquired a new position in DexCom during the second quarter valued at approximately $219,000. Finally, Suntrust Banks Inc. acquired a new position in DexCom during the second quarter valued at approximately $230,000. Institutional investors and hedge funds own 99.37% of the company’s stock.
Shares of DexCom (NASDAQ:DXCM) traded down 2.58% on Monday, hitting $85.40. 622,628 shares of the stock traded hands. DexCom has a 52 week low of $47.92 and a 52 week high of $96.38. The firm’s 50 day moving average is $91.93 and its 200 day moving average is $77.09. The firm’s market capitalization is $7.16 billion.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.12. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. The business had revenue of $137.30 million for the quarter, compared to analyst estimates of $132.48 million. During the same quarter in the prior year, the firm earned ($0.05) EPS. The firm’s quarterly revenue was up 47.3% compared to the same quarter last year. On average, analysts expect that DexCom will post ($0.57) EPS for the current fiscal year.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.